Lv3
380 积分 2021-09-12 加入
No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk Myeloma
7小时前
求助中
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study
7小时前
求助中
Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study
7小时前
求助中
PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma
7小时前
求助中
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial
7小时前
求助中
Proposal for Diagnostic Criteria for Manifestations of Chronic Graft-versus-Host Disease in the CNS
11小时前
已完结
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH)
11小时前
求助中
Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review
11小时前
已完结
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial
11小时前
已关闭
MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma
11小时前
已完结
皖公网安备34019202002308
